APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
-0.10% today
Updated 2026-04-29
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.4M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+5.5
Quality
C+4.0
Profitability
C5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
-2.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$40.93
-0.05%
12-Month target
$1.22
-97.02%
Intrinsic (DCF)
$193.03
Margin of safety
+88.44%
2 Strong Buy5 Buy13 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 88.44% below intrinsic value
Risks
- Altman Z -2.39 — distress zone
- Thin margins at 2.23%
- Negative free cash flow $-14.38M
- Revenue declining -5.90% QoQ
- P/E 227.50x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $75.42M | $396.59M | $781.37M | $1.00B | $1.00B |
| Net income | $-652.17M | $-528.63M | $-197.88M | $22.39M | $-58.95M |
| EPS | — | — | — | — | $0.18 |
| Free cash flow | $-515.27M | $-595.51M | $-88.27M | $45.01M | $-14.38M |
| Profit margin | -864.70% | -133.29% | -25.32% | 2.23% | 2.23% |
Peer comparison
Smart narrative
Apellis Pharmaceuticals Inc trades at $40.95. representing a P/E of 227.50x trailing earnings. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -2.39, it sits in the distress. TTM revenue stands at $1.00B. with profit margins at 2.23%. Our DCF model estimates intrinsic value at $193.03.
Frequently asked questions
What is Apellis Pharmaceuticals Inc's stock price?
Apellis Pharmaceuticals Inc (APLS) trades at $40.95.
Is Apellis Pharmaceuticals Inc overvalued?
Smart Value Score 27/100 (Grade F, Strong Sell). DCF value $193.03.
What is the price target of Apellis Pharmaceuticals Inc (APLS)?
The analyst target price is $40.93, representing -0.0% downside from the current price of $40.95.
What is the intrinsic value of Apellis Pharmaceuticals Inc (APLS)?
Based on our DCF model, intrinsic value is $193.03, a +88.4% margin of safety versus $40.95.
What is Apellis Pharmaceuticals Inc's revenue?
TTM revenue is $1.00B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-2.39 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.22x
ROE7.48%
Beta-0.20
50D MA$28.49
200D MA$24.79
Shares out0.13B
Float0.08B
Short ratio—
Avg volume5.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—